Nothing on this site is intended for human or veterinary use. PeptideBasics101 exists for general awareness: it collects publicly available information from across the internet and keeps it in one place for research and entertainment purposes only. Nothing here is medical advice. Statements here are our summaries of public sources and have not been reviewed or endorsed by the FDA or any regulatory body. This is information gathering, not guidance.

PeptideBasics101

peptide

Cagrilintide

A long-acting copy of the hormone amylin, tested alone and with semaglutide; the mix is under FDA review, not approved.

An investigational long-acting amylin analogue from Novo Nordisk, studied alone and combined with semaglutide as CagriSema, which is under FDA review. Not yet approved.

Data refreshed 2026-11-01 · Based on 19 published references

At a glance

FDA approved
No. Still in clinical trials.
Potential results
  • 10.8% weight loss alone in 26 weeks (trial vs placebo)
  • 20.4% weight loss combined with semaglutide (large trial)
  • Less weight loss than tirzepatide (head-to-head trial)
  • Lower blood sugar in type 2 diabetes (trials vs placebo)
  • Slightly lower blood sugar than semaglutide alone in type 2 diabetes (large trial)

Unverified, online reports only: appetite suppression alongside tirzepatide or retatrutide, often after a weight-loss stall.

Dose
Study doses: see the Scientific view
Converter: mg, mL and syringe units
Storage
Powder: fridge (2–8 °C) for the short term, freezer (−20 °C) for the long term; after mixing, fridge for up to 28 days (general guidance, not tested for this compound).
Side effects and warnings
  • The most common side effects are nausea, vomiting, constipation and diarrhea. Most were mild to moderate. Most happened while the dose was being raised.
  • Other side effects include less appetite, tiredness and reactions where the shot is given.
  • When used with semaglutide, semaglutide's warnings also apply. These include pancreas swelling (pancreatitis), gallbladder problems and thyroid findings in rodents.

A summary of the sources on this page, not medical advice.

What else trials studied for weight loss, blood sugar and metabolism: see the research quiz.

Names

Generic: cagrilintide

Also called: NNC0174-0833, CagriSema (with semaglutide), cagri, AM833, NN9833

Regulatory (US)

FDA approval: investigational

503A compounding: restricted
Compounding is limited to the circumstances described under Regulatory picture; not a general permission.

Molecule

Formula: C194H312N54O59S2

MW: 4409 g/mol

CAS: 1415456-99-3

PubChem entry

Origin

Discovered by: Novo Nordisk research

Developer: Novo Nordisk

What it is

Cagrilintide is a lab-made copy of amylin. Amylin is a hormone. The pancreas releases it along with insulin after meals. Amylin slows how fast the stomach empties. It also tells the brain you are full. It does this by a different route than GLP-1 drugs. Novo Nordisk designed cagrilintide to last a week. They also made it so it does not clump. Clumping is a known problem with natural amylin.

On its own, it caused slightly more weight loss than liraglutide in a mid-stage trial. It has also been combined with semaglutide in one pen. That combination is called CagriSema. In the main Phase 3 trial, CagriSema caused about 20% weight loss. Neither cagrilintide nor CagriSema is approved yet. CagriSema is under FDA review.

Cagrilintide (NNC0174-0833) is a 37-residue amylin analogue with substitutions at residues prone to β-sheet aggregation and a C20 fatty diacid attached through a linker for albumin binding. It is a dual amylin and calcitonin receptor agonist (DACRA), acting on calcitonin receptor and RAMP-associated amylin receptor complexes in the area postrema and hypothalamus. In a Phase 1b study its half-life was 159–195 hours, against 145–165 hours for co-administered semaglutide. The combination rationale is additive appetite suppression through non-overlapping central pathways, with the amylin component possibly offsetting some GLP-1 receptor agonist tolerance.

Who made it and when

Novo Nordisk made it in the mid-2010s. The company published the chemistry in 2021. It then tested the drug alone and with semaglutide. The large Phase 3 trials are called REDEFINE. They started in 2022. The first results came out in December 2024. Novo Nordisk asked the FDA to approve CagriSema in December 2025. In September 2026 the company said it expects the US decision in the last 3 months of 2026.

Kruse and colleagues at Novo Nordisk described the medicinal chemistry in 2021. Phase 2 monotherapy (n=706) reported in 2021; Phase 2 CagriSema in T2D reported in 2023. The REDEFINE program includes REDEFINE 1 (obesity), REDEFINE 2 (obesity with T2D), REDEFINE 3 (cardiovascular outcomes, event-driven) and REDEFINE 4 (head-to-head vs tirzepatide). Novo Nordisk announced on 2025-12-18 that it had submitted a New Drug Application for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) for weight management in adults with obesity, or overweight with comorbidities. No FDA approval had been announced as of 2026-11-01; the company stated on 2026-10-29 that CagriSema is not approved in the United States or anywhere else, and its 2026-09-21 Capital Markets Day deck guided to a US decision in the fourth quarter of 2026. Patents are held by Novo Nordisk.

What the data say

Alone, the highest dose of cagrilintide caused about 11% weight loss in 26 weeks. That was slightly more than liraglutide.

With semaglutide, the Phase 3 REDEFINE 1 trial showed about 20% weight loss over 68 weeks. Semaglutide alone gave 15%. A dummy treatment (placebo) gave 3%. If everyone had stayed on treatment, the figure was about 23%. Many people did not stay on the full dose.

In people with diabetes, CagriSema caused about 14% weight loss. In a head-to-head trial, it did not do as well as tirzepatide.

Three more trials were published in 2026. In people with type 2 diabetes on metformin, CagriSema lowered long-term blood sugar (HbA1c) a little more than semaglutide alone. In people on insulin, it lowered HbA1c by 2.3 points versus 0.7 with placebo. In Japan and Taiwan, it gave about 18% weight loss versus 12% with semaglutide. Stomach and gut side effects were about twice as common as with placebo across the diabetes trials.

Phase 2 monotherapy: 4.5 mg gave −10.8% at 26 weeks vs −3.0% placebo. REDEFINE 1 (n=3,417): CagriSema −20.4% vs semaglutide 2.4 mg −14.9%, cagrilintide 2.4 mg −11.5%, placebo −3.0% at 68 weeks (treatment-policy); −22.7% vs −2.3% by trial-product estimand. The flexible-dosing protocol meant only 57.3% of CagriSema participants were on the full 2.4/2.4 mg dose at the end of treatment. REDEFINE 2 (T2D, n=1,206): −13.7% vs −3.4%. REDEFINE 4 (n=809, open-label, 84 weeks) did not show non-inferiority to tirzepatide 15 mg (−23.0% vs −25.5% if all adhered). Gastrointestinal adverse events were the main tolerability issue, reported in 79.6% vs 39.9% on placebo in REDEFINE 1. A post hoc analysis of REDEFINE 1 reported systolic blood pressure −10.9 mmHg with CagriSema vs −2.8 mmHg with placebo (Verma et al., Hypertension 2026;83(2):e26055).

Phase 3a publications in 2026: REIMAGINE 2 (Buse et al., Lancet Diabetes Endocrinol 2026;14(8):662–677; n=2,713 with T2D on metformin ± SGLT2 inhibitor, 68 weeks) reported HbA1c −1.91 vs −1.75 percentage points for CagriSema 2.4/2.4 mg vs semaglutide 2.4 mg (ETD −0.16, 95% CI −0.27 to −0.05, efficacy estimand) with adverse events in 86.9% vs 81.2%; REIMAGINE 3 (Rosenstock et al., Lancet 2026;408:38–51; n=274 on basal insulin, 40 weeks) reported HbA1c −2.33% vs −0.66% with placebo (ETD −1.68, −1.95 to −1.41) and no severe hypoglycaemia; REDEFINE 5 (Yamauchi et al., Lancet Diabetes Endocrinol 2026;14(6):450–462; n=331, Japan and Taiwan, 68 weeks) reported −18.4% vs −11.9% body weight with semaglutide (ETD −6.5 points, −8.4 to −4.6, trial-product estimand). A meta-analysis of 6 RCTs in T2D (Kow et al., Diabetes Obes Metab 2026, doi 10.1111/dom.71485) put the relative risk of gastrointestinal adverse events at 2.27 vs placebo. Company data, not peer reviewed: Novo Nordisk’s September 2026 deck gives REDEFINE 9 weight loss at 68 weeks as 20.95% (1.0/1.0 mg) and 20.75% (1.7/1.7 mg) by the efficacy estimand, with discontinuation for adverse events in 4.9%, 2.9% and 4.9% (placebo); primary results are due as a poster at ObesityWeek on 2026-11-15.

Regulatory picture

Cagrilintide is not approved anywhere. CagriSema was sent to the FDA for review in December 2025. It was still under review on 1 November 2026. Novo Nordisk said on 29 October 2026 that CagriSema is not approved in the United States or anywhere else, and expects the US decision in the last 3 months of 2026. Cagrilintide on its own is in late-stage (Phase 3) trials called RENEW; the company says it expects to launch it in 2028 if approved. The FDA says cagrilintide cannot legally be used in compounding in the United States. It is not one of the 6 peptides covered by the US health department’s draft policy of October 2026 that eases enforcement on some compounded peptides. Compounding means pharmacies mixing their own versions. Cagrilintide is not part of any FDA-approved drug. Anything sold online under this name is an unapproved drug.

Cagrilintide is investigational under IND. It is not a component of an approved product and has no USP monograph. FDA’s guidance page on unapproved GLP-1 drugs states that cagrilintide cannot be used in compounding under federal law, so neither the 503A nor the 503B pathway is available. FDA’s page carried a “current as of 10/01/2026” date when checked for this update, with that wording unchanged, and no FDA warning letter in the 2026-08-24 round to “research use” sellers named cagrilintide as a product. Cagrilintide is also not among the six peptides covered by the HHS draft enforcement-discretion policy of 2026-10-30 (docket HHS-OASH-2026-0496). The CagriSema NDA was submitted to the FDA in December 2025. As of 2026-11-01 no decision had been announced: Novo Nordisk’s 2026-09-21 Capital Markets Day deck expects the “CagriSema US decision for weight management” in the fourth quarter of 2026, the REDEFINE 11 readout in the first quarter of 2027 and the CagriSema HD readout in the first half of 2028, and lists the cagrilintide monotherapy programme RENEW as “Phase 3 ongoing, Expected launch 2028”; on 2026-10-29 the company stated that “CagriSema is not approved in the United States or anywhere else”. Registered since 2025–2026: RENEW 1 and RENEW 2 (NCT07220642, NCT07220759; cagrilintide vs placebo, 64 weeks), NCT07564414 (CagriSema at two dose levels vs semaglutide, Phase 3, recruiting, 2,500 planned, 72 weeks) and NCT07745504 (RENEW 4, cagrilintide in two presentations vs placebo, recruiting, 285 planned). Any approval would cover the fixed-dose combination product, not cagrilintide as a stand-alone drug.

Dose

Doses reported in trials and studies

How dosing worked in the studies

A Phase 2 study included 706 adults with obesity or overweight. Each was given one treatment, assigned by chance. Options were cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg as a shot under the skin once a week. Others got a dummy treatment (placebo) or liraglutide 3 mg daily. The study lasted 26 weeks. A Phase 1b trial gave 96 adults either cagrilintide (target 0.16 to 4.5 mg, by group) or placebo. Everyone also got semaglutide 2.4 mg. Both doses were raised every 4 weeks over 16 weeks. Then they were kept steady for 4 weeks. The REDEFINE trials tested CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg once a week). REDEFINE 1 compared it with placebo and with each drug alone for 68 weeks. REDEFINE 2 compared it with placebo for 68 weeks. REDEFINE 4 compared it with tirzepatide 15 mg for 84 weeks.

Doses used in the studies are in the Scientific view.

Study doses are not personal dosing instructions. Reading doses safely: how concentration and syringe markings work.

Doses reported in studies, exactly as the cited trial reported them. They are not personal dosing instructions. Population, route and schedule matter more than the number.

TrialPhaseStatusPopulationDoseResult
Phase 2 monotherapy study
NCT03856047		 2Completed706 adults with obesity or overweight plus hypertension or dyslipidaemia, no diabetes0.3, 0.6, 1.2, 2.4 or 4.5 mg subcutaneous once weekly vs placebo and liraglutide 3 mg daily, 26 weeks−10.8% body weight at 4.5 mg vs −3.0% placebo and −9.0% liraglutide at 26 weeks (Lau et al., Lancet 2021)
Phase 2 CagriSema in type 2 diabetes
NCT04982575		 2Completed92 adults with type 2 diabetes and overweight or obesityCagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly vs each alone, 32 weeks−15.6% body weight with CagriSema vs −5.1% semaglutide and −8.1% cagrilintide; HbA1c −2.2 points (Frias et al., Lancet 2023)
REDEFINE 1
NCT05567796		 3Active, not recruiting (primary 68-week results published)3,417 adults with obesity or overweight plus comorbidity, no diabetesCagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly (CagriSema) vs each alone vs placebo, 68 weeks−20.4% body weight with CagriSema vs −14.9% semaglutide, −11.5% cagrilintide and −3.0% placebo, treatment-policy estimand (Garvey et al., NEJM 2025)
REDEFINE 2
NCT05394519		 3Completed1,206 adults with obesity or overweight and type 2 diabetesCagriSema 2.4 mg / 2.4 mg once weekly vs placebo, 68 weeks−13.7% body weight vs −3.4% placebo, treatment-policy estimand (Davies et al., NEJM 2025)
REDEFINE 4
NCT06131437		 3Completed809 adults with obesity (BMI 30 or higher) and at least one comorbidity, no diabetesCagriSema 2.4 mg / 2.4 mg once weekly vs tirzepatide 15 mg once weekly, open-label, 84 weeksDid not meet its primary endpoint of non-inferiority to tirzepatide: −23.0% vs −25.5% if all participants adhered, −20.2% vs −23.6% by treatment-regimen estimand (Novo Nordisk, February 2026)
REDEFINE 3
NCT05669755		 3Active, not recruiting (primary completion estimated September 2027)7,101 adults enrolled (7,076 randomised per the design paper) at 575 sites in 24 countries; event-driven cardiovascular outcomes trialCagriSema once weekly vs placebo, event-driven; the dose level is not stated in the sources used hereNo results. The design paper (Cavender et al., Am Heart J 2026) describes a MACE-3 non-inferiority test followed by a MACE-4 superiority test.
RENEW 1 (cagrilintide monotherapy)
NCT07220642		 3Active, not recruiting (started November 2025; primary completion estimated May 2027)300 adults with overweight or obesity, planned; Novo NordiskCagrilintide subcutaneous once weekly vs placebo (2:1), 64 weeks; the dose level is not stated in the registry—
RENEW 2 (cagrilintide monotherapy, type 2 diabetes)
NCT07220759		 3Active, not recruiting (started November 2025; primary completion estimated May 2027)330 adults with overweight or obesity and type 2 diabetes, planned; Novo NordiskCagrilintide subcutaneous once weekly vs placebo (2:1), 64 weeks; the dose level is not stated in the registry—

Doses in other published studies

Published studies not listed in the trials table above: smaller or unregistered human studies first, then animal and cell studies. Doses are shown exactly as each study reported them. Animal studies report weight-based doses, absolute amounts or concentrations; none translates directly to people, and none is converted here.

SubjectsDesignDoseFindingSource
Humans: 96 otherwise healthy adults aged 18-55 with BMI 27.0-39.9 kg/m2 (95 exposed), single US centreRandomised, placebo-controlled, multiple-ascending-dose Phase 1b trial in six sequential cohorts (NCT03600480); no lifestyle interventionOnce-weekly subcutaneous cagrilintide 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg, or matched placebo (3:1), each with once-weekly subcutaneous semaglutide 2.4 mg; both co-escalated in 4-week intervals over 16 weeks, then 4 weeks at the target dose (end of treatment week 20), then 5 weeks follow-upAt week 20, mean weight loss was 15.7% with cagrilintide 1.2 mg and 17.1% with 2.4 mg vs 9.8% with pooled placebo, and 15.4% with 4.5 mg vs 8.0% with matched placebo (all with semaglutide); most adverse events were mild to moderate, and 37% of them were gastrointestinal.Enebo LB et al., Lancet, 2021
Humans: 33 adults with normal renal function or mild, moderate or severe renal impairment; 32 adults with normal hepatic function or mild, moderate or severe hepatic impairmentTwo single-dose pharmacokinetic studies (NCT04209049, NCT05564104)Single subcutaneous dose of cagrilintide 0.6 mg (renal impairment study) or 0.9 mg (hepatic impairment study); exposure assessed from day 1 to day 36 (renal) or day 39 (hepatic)Within small samples, cagrilintide exposure (AUC and Cmax) was similar across impairment groups, and no serious adverse events, adverse-event withdrawals or deaths were reported.Nielsen MJF et al., Clinical Pharmacokinetics, 2026
Humans: 105 healthy participants (53 cagrilintide, 52 placebo)Double-blind, randomised, placebo-controlled thorough QT study (NCT05804162) with nested cross-over moxifloxacin positive controlOnce-weekly subcutaneous cagrilintide, dose escalated to 4.5 mg (escalation schedule and total duration not stated in the abstract); placebo arms received a single 400 mg oral moxifloxacin dose as positive controlNo clinically relevant QTcF prolongation occurred after the last 4.5 mg dose; the upper 90% confidence limits of placebo-adjusted QTcF change stayed below 10 ms at 12, 24, 48 and 72 hours.Gabe MBN et al., Diabetes, Obesity and Metabolism, 2024
Humans: 189 adults with type 2 diabetes inadequately controlled on diet and exercise, 42 sites in six countriesRandomised, double-blind, placebo-controlled Phase 3a trial, REIMAGINE 1 (NCT06323174)Once-weekly subcutaneous cagrilintide 2.4 mg plus semaglutide 2.4 mg, or cagrilintide 1.0 mg plus semaglutide 1.0 mg, vs dose-matched placebo, 40 weeksBy the efficacy estimand, HbA1c fell 1.8 percentage points (2.4 mg each) and 1.5 percentage points (1.0 mg each) vs 0.1 with placebo, and body weight fell 13.8% and 11.8% vs 1.4% with placebo.Aroda VR et al., Lancet Diabetes & Endocrinology, 2026
Humans: 2,713 adults with type 2 diabetes on metformin with or without an SGLT2 inhibitorRandomised, double-blind Phase 3a trial, REIMAGINE 2 (NCT06065540), 68 weeksOnce-weekly subcutaneous cagrilintide 2.4 mg plus semaglutide 2.4 mg (CagriSema) vs semaglutide 2.4 mg alone, 68 weeksBy the efficacy estimand, HbA1c fell 1.91 percentage points with CagriSema vs 1.75 with semaglutide alone (estimated treatment difference −0.16, 95% CI −0.27 to −0.05); adverse events were reported in 86.9% vs 81.2%.Buse JB et al., Lancet Diabetes & Endocrinology, 2026
Humans: 274 adults with type 2 diabetes treated with basal insulinRandomised, placebo-controlled Phase 3a trial, REIMAGINE 3 (NCT06323161), 40 weeksOnce-weekly subcutaneous CagriSema vs placebo, added to basal insulin, 40 weeks; the dose level is not stated in the abstract used hereHbA1c fell 2.33 percentage points with CagriSema vs 0.66 with placebo (estimated treatment difference −1.68, 95% CI −1.95 to −1.41); no severe hypoglycaemia was reported.Rosenstock J et al., Lancet, 2026
Humans: 331 adults in Japan and Taiwan (weight-management trial)Randomised Phase 3a trial, REDEFINE 5 (NCT05813925), 68 weeksOnce-weekly subcutaneous CagriSema vs semaglutide, 68 weeks; the dose levels are not stated in the abstract used hereBody weight fell 18.4% with CagriSema vs 11.9% with semaglutide (estimated treatment difference −6.5 percentage points, 95% CI −8.4 to −4.6), trial-product estimand.Yamauchi T et al., Lancet Diabetes & Endocrinology, 2026
Rats: diet-induced obese male Sprague Dawley rats (plus normal-weight rats for activity telemetry)Treatment studies of about 3 weeks with indirect calorimetry and pair-fed and weight-matched controlsSubcutaneous once daily: CagriSema 0.5 + 0.5 nmol/kg on day 1, 1 + 1 nmol/kg on day 2, then 2 + 2 nmol/kg/day to the end; cagrilintide alone 2 nmol/kg/day, or high-dose cagrilintide 10 nmol/kg/day from day 1The authors report 12% weight loss with CagriSema alongside a 39% cut in food intake, and attribute about one-third of the weight loss to preserved energy expenditure; cagrilintide 2 nmol/kg/day alone produced about half the weight loss of the combination.Jacobsen JM et al., Nature Metabolism, 2025
Rats: diet-induced obese male rats; lean, aged, chow-fed male Sprague-Dawley rats for a taste-aversion testPreclinical combination study of cagrilintide with retatrutide vs each alone and vs matched-dose combinations incorporating semaglutide or tirzepatideDaily subcutaneous cagrilintide, retatrutide, cagrilintide-retatrutide or vehicle for 13 days at a dose stated as 30 nmol/kg (Extended Data Fig. 7 legend); a single subcutaneous cagrilintide-retatrutide dose of 0.1, 0.3, 1, 3 or 10 nmol/kg in the taste-aversion test (Extended Data Fig. 6 legend)The abstract reports that daily co-administration produced dose-dependent reductions in body weight and food intake that exceeded equimolar monotherapies and matched-dose combinations incorporating semaglutide or tirzepatide.Petersen J et al., Nature Metabolism, 2026

Mixing examples reported by protocol websites

Examples for the freeze-dried powder, as reported by protocol websites, not taken from studies. The water amount only sets the concentration (how much is in each mL); it does not change how much of the compound is in the vial. Each concentration assumes the vial really holds its labelled amount and the final liquid volume equals the water added.

VialWater addedConcentration
5 mg2.0 mL2.5 mg/mL
10 mg3.0 mL3.33 mg/mL
10 mg2.0 mL5.0 mg/mL
  1. Clean the rubber tops of both vials with an alcohol swab.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl or roll gently until the powder dissolves; protocol sites advise against shaking.
  4. The liquid should be clear. If it is cloudy or has specks in it, do not use it. Clear liquid does not show that the product is pure, the right strength or sterile.
  5. Write the date and the concentration on the vial, and keep it in the fridge (2–8 °C). No safe storage time after mixing has been established for these products.

Products sold as "research peptides" have not gone through FDA review for safety, effectiveness or quality. Bacteriostatic water does not sterilize a contaminated powder. It contains benzyl alcohol, and its label says it is not for use in newborns. To work out a volume from your own numbers, use the converter.

Doses described in clinical or compounding practice

From FDA labels and documents, other regulators, published reviews and professional references, as each source states them. Unless a source says otherwise, these describe practice or proposals, not results tested in trials. Reading doses safely: how concentration and syringe markings work.

Doses reported in online communities (untested)

Unverified, and not a recommendation. These are amounts people describe in online forums such as Reddit, collected so researchers can see how practice differs from the evidence. These forum accounts are not clinical evidence, even where they overlap studied doses. Products sold online as "research peptides" are not FDA approved, and their identity, purity and strength are not verified; they can be mislabeled, contaminated or wrongly dosed.

What people report

In the threads reviewed (r/Peptides, r/Retatrutide and r/tirzepatidecompound, 2024-2026), posters described injecting cagrilintide at roughly 0.1-1 mg once or twice a week, with two describing about 2-4 mg a week, often alongside tirzepatide or retatrutide. The main disagreement was about strength: some described difficulty eating at low amounts, while others described little effect or an effect that faded. Side effects described included fatigue (raised repeatedly), gastrointestinal complaints (nausea, vomiting, bloating, sulfur burps, diarrhoea) and feeling full and hungry at the same time.

How this compares with the studies

Published human studies gave cagrilintide as once-weekly subcutaneous injections of 0.16-4.5 mg, or single 0.6 or 0.9 mg doses in pharmacokinetic studies, alone or with semaglutide. No human trial combining it with tirzepatide or retatrutide was found for this review. The threads involve other drug combinations, unverified research-grade material and self-selected users, so their amounts cannot be compared with trial exposure, safety or efficacy.

Open questions a study would need to answer

Threads consulted, checked 2026-09-26: Reta and Cagri are the real deal (r/Peptides) · Not a fan of Cagri (r/Peptides) · Cagri Question (r/Peptides) · Cagri (r/Peptides) · Cagri (r/Retatrutide) · Reta or Cagri? (r/Retatrutide) · Reta + Cagri (r/Retatrutide) · Stacking (r/tirzepatidecompound)

Enforcement history

Side effects and warnings

Full lists are in the .

Reported side effects

Interactions

Contraindications

Storage

No approved product exists, so there is no label storage guidance. Supplier claims for research-grade material are not label data.

General storage guidance commonly given for freeze-dried research peptides and powders, not stability data for this substance. Storage conditions and usable life depend on the specific product and formulation; follow its documented instructions.

ConditionTemperature
Temporary (transportation), in powdered form15 °C – 25 °C / 59 °F – 77 °F
Short term (1–3 years)2 °C – 8 °C / 36 °F – 46 °F
After reconstitution (28 days)2 °C – 8 °C / 36 °F – 46 °F
Long term (2–5 years)−20 °C / −4 °F or below

Product characteristics

Form: Investigational solution for subcutaneous injection; in CagriSema, co-formulated with semaglutide in one pen

Stability: Lipidated with a C20 fatty diacid; half-life of 159–195 hours (about 7–8 days) in a Phase 1b study supports once-weekly dosing

Compound information

Synthetic 37-residue amylin analogue with substitutions to prevent fibrillation and a C20 diacid for albumin binding. It is a dual amylin and calcitonin receptor agonist. PubChem lists the formula as C194H312N54O59S2 (CID 171397054).

Molecule, patents, enforcement history, full trial tables and compound details are in the .

Common questions

What is Cagrilintide?

Cagrilintide is a lab-made copy of amylin. Amylin is a hormone. The pancreas releases it along with insulin after meals. Amylin slows how fast the stomach empties. It also tells the brain you are full. It does this by a different route than GLP-1 drugs. Novo Nordisk designed cagrilintide to last a week. They also made it so it does not clump. Clumping is a known problem with natural amylin.

Is Cagrilintide FDA approved?

Still in clinical trials; not FDA approved.

What have studies found?

How was it dosed in studies?

A Phase 2 study included 706 adults with obesity or overweight. Each was given one treatment, assigned by chance. Options were cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg as a shot under the skin once a week. Others got a dummy treatment (placebo) or liraglutide 3 mg daily. The study lasted 26 weeks. A Phase 1b trial gave 96 adults either cagrilintide (target 0.16 to 4.5 mg, by group) or placebo. Everyone also got semaglutide 2.4 mg. Both doses were raised every 4 weeks over 16 weeks. Then they were kept steady for 4 weeks. The REDEFINE trials tested CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg once a week). REDEFINE 1 compared it with placebo and with each drug alone for 68 weeks. REDEFINE 2 compared it with placebo for 68 weeks. REDEFINE 4 compared it with tirzepatide 15 mg for 84 weeks.

What are the side effects and warnings?

Is it legal to buy as a "research peptide"?

Products sold as "research use only" or "not for human consumption" are not approved for use in people. That label does not make them legal to sell for human use, and their contents are not checked by any regulator.

References

This page summarises the published sources below. PeptideBasics101 does no original research. Trial doses and results are reported as the cited study or label reported them. Sources can themselves be wrong or superseded; if you find a statement here that does not match its source, please tell us through our corrections process. Sources were last checked on 2026-11-01.

Based on 19 published references
  1. Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. Lancet 2021 (doi.org)
  2. Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes. Lancet 2023 (doi.org)
  3. Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). NEJM 2025 (nejm.org)
  4. Davies MJ et al. Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). NEJM 2025 (nejm.org)
  5. Kruse T et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem 2021 (doi.org)
  6. Novo Nordisk: CagriSema submitted to the FDA (press release, 2025-12-18) (prnewswire.com)
  7. Novo Nordisk: REDEFINE 4 headline results (company announcement, 2026-02-23) (globenewswire.com)
  8. Novo Nordisk: Capital Markets Day 2026, obesity presentation (2026-09-21) (novonordisk.com)
  9. Novo Nordisk: REDEFINE 9 results to be presented at ObesityWeek (company announcement, 2026-10-29) (novonordisk.com)
  10. Cavender MA et al. Design of REDEFINE 3, the CagriSema cardiovascular outcomes trial. Am Heart J 2026 (pubmed.ncbi.nlm.nih.gov)
  11. Buse JB et al. CagriSema vs semaglutide in type 2 diabetes on metformin (REIMAGINE 2). Lancet Diabetes Endocrinol 2026;14(8):662–677 (pubmed.ncbi.nlm.nih.gov)
  12. Rosenstock J et al. CagriSema in type 2 diabetes on basal insulin (REIMAGINE 3). Lancet 2026;408(10549):38–51 (pubmed.ncbi.nlm.nih.gov)
  13. Yamauchi T et al. CagriSema vs semaglutide in Japan and Taiwan (REDEFINE 5). Lancet Diabetes Endocrinol 2026;14(6):450–462 (pubmed.ncbi.nlm.nih.gov)
  14. Verma S et al. Blood pressure with CagriSema in REDEFINE 1 (post hoc). Hypertension 2026;83(2):e26055 (pubmed.ncbi.nlm.nih.gov)
  15. Kow CS et al. Cagrilintide-semaglutide in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2026 (pubmed.ncbi.nlm.nih.gov)
  16. ClinicalTrials.gov: NCT07564414, CagriSema at two dose levels vs semaglutide (Phase 3) (clinicaltrials.gov)
  17. ClinicalTrials.gov: NCT07745504, RENEW 4, cagrilintide in two presentations vs placebo (Phase 3) (clinicaltrials.gov)
  18. HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability (Federal Register, 2026-10-30) (govinfo.gov)
  19. PubChem: cagrilintide (pubchem.ncbi.nlm.nih.gov)

Clinical trial entries in the table above link to their ClinicalTrials.gov registry records. Spotted an error? See corrections.

Ask Sgt. Pep